Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Thomas BieberNorito KatohEric L SimpsonMarjolein de Bruin-WellerDiamant ThaҫiAntonio TorreloAngelina SontagSusanne GrondMaher IssaXiaoyu LuTracy CardilloKatrin HolzwarthJacob P ThyssenPublished in: The Journal of dermatological treatment (2023)
NCT02576938 (JAHG), NCT03334396 (JAHL; BREEZE-AD1), NCT03334422 (JAHM; BREEZE-AD2), NCT03334435 (JAHN; BREEZE-AD3), NCT03428100 (JAIN; BREEZE-AD4), NCT03435081 (JAIW; BREEZE-AD5), NCT03559270 (JAIX; BREEZE-AD6), NCT03733301 (JAIY; BREEZE-AD7).